Long-term clinical outcome of elderly patients with acute coronary syndrome treated with early percutaneous coronary intervention: Insights from the BASE.

Slides:



Advertisements
Similar presentations
Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.
Advertisements

Samsung Medical Center Sungkyunkwan University School of Medicine Hyeon-Cheol Gwon, Joo Yong Hahn, Young Bin Song, Kyung Woo Park, Yang Soo Jang, Hyo-Soo.
RESOLUTE US One-Year Clinical Outcomes from the Pivotal Multicenter RESOLUTE US Study Objective To evaluate the clinical effectiveness of the Resolute.
TLR Funnel plot (according to outcomes) for studies included in the meta-analysis Death A TVR B MACE DC SE(log OR)
ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Fractional Flow Reserve Versus Angiography for Guiding.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Comprehensive Meta-Analysis of Safety and Efficacy.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Relationship between heparin anticoagulation and.
1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.
Date of download: 9/16/2016 Copyright © The American College of Cardiology. All rights reserved. From: 5-Year Clinical Outcomes of the ARTS II (Arterial.
From: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention:
on behalf of the Investigators
Evaluation of XIENCE V Everolimus-Eluting and Taxus Express2 Paclitaxel-Eluting Coronary Stents in Patients With Jailed Side Branches From the SPIRIT.
The BVS-SAVE Italian registry: Bioresorbable Vascular Scaffolds
Usefulness of Preprocedure High-Sensitivity C-Reactive Protein to Predict Death, Recurrent Myocardial Infarction, and Stent Thrombosis According to Stent.
Influence of Diabetes Mellitus on Clinical Outcomes Following Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial.
Figure 2 Kaplan–Meier estimates of event-free survival (survival to the combined endpoint). From: Long-term outcomes of patients with acute myocardial.
Volume 54, Issue 1, Pages (August 2009)
“Per Protocol” Definitions of Stent Thrombosis
LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.
On behalf of all principal COMPARE II investigators:
TAXUS IV Trial Slow-rate release polymer-based paclitaxel-eluting stent compared with bare stent in patients with single de novo coronary lesions Presented.
Comparison of Outcomes in Patients With Versus Without Diabetes Mellitus After Revascularization With Everolimus- and Sirolimus-Eluting Stents (from the.
Circ Cardiovasc Interv
FINAL FIVE-YEAR CLINICAL OUTCOMES OF THE NOBORI2 TRIAL
Circ Cardiovasc Interv
Impact of calcium on procedural and clinical outcomes in lesions treated with bioresorbable vascular scaffolds - A prospective BRS registry study  Jiang.
Giuseppe Biondi Zoccai
Introduction The American Journal of Medicine
American College of Cardiology Presented by Dr. Stephan Windecker
European Society of Cardiology 2003
Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year.
REALITY: 8 month results
Figure 2 Ischaemic and bleeding outcomes in the major clinical trials
Stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: A meta-analysis of comparative studies  Hisato Takagi,
Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-year Outcomes of the EVERBIO.
Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease 
J. Trevor Posenau, MD, Daniel M. Wojdyla, MS, Linda K
Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction  P.-G. Chassot, A. Delabays, D.R. Spahn 
The American College of Cardiology Presented by Dr. Raimund Erbel
SIRIUS: A U.S. Multicenter, Randomized, Double-Blind Study of the SIRolImUS-Eluting Stent in De Novo Native Coronary Lesions Presented at TCT 2002.
American Heart Association Presented by Dr. Julinda Mehilli
Efficacy and Safety of Thrombin-Receptor Antagonist (Atopaxar and Vorapaxar) in Patients with Acute Coronary Syndrome or Coronary Artery Disease—A Meta-Analysis.
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
Three-Year Outcomes of Multivessel Revascularization in Very Elderly Acute Coronary Syndrome Patients  Brett C. Sheridan, MD, Sally C. Stearns, PhD, Joseph.
Potential conflicts of interest
On behalf of all principal COMPARE II investigators:
(p = 0.32 for noninferiority)
Role of Stenting in Acute MI: PAMI Stent Pilot Trial
Early and long-term outcomes of coronary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris  Toshihiro Fukui,
Volume 371, Issue 9627, Pages (May 2008)
Comparison of prescription rates and clinical outcomes in acute coronary syndrome patients who underwent percutaneous coronary intervention using different.
Do the EXCEL and NOBLE Trial Results Change Meta-Analysis Findings?
Presented at TCT 2006.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
Pulse pressure for selecting the optimal cardiac strategy in patients with type 2 diabetes and coronary artery disease  Tetsuro Tsujimoto, Hiroshi Kajio 
Impact of final kissing balloon inflation after simple stent implantation for the treatment of non-left main true coronary bifurcation lesions in patients.
High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE.
SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.
Stent Versus Off-Pump Coronary Bypass Grafting in the Second-Generation Drug- Eluting Stent Era  Gijong Yi, MD, PhD, Hyun-Chel Joo, MD, Young-Nam Youn,
Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial
IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.
Long-term outcome of dialysis patients in the United States with coronary revascularization procedures  Charles A. Herzog, M.D., Jennie Z. Ma, Allan J.
The American College of Cardiology Presented by Dr. A. Abazid
Figure 1 Design of trials included in individual patient data meta-analysis. Unless provided in the caption above, the following copyright applies to the.
Improved Long-Term Survival for Diabetic Patients With Surgical Versus Interventional Revascularization  Paul Kurlansky, MD, Morley Herbert, PhD, Syma.
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
M. N. Vicenzi, T. Meislitzer, B. Heitzinger, M. Halaj, L. A
Presentation transcript:

Long-term clinical outcome of elderly patients with acute coronary syndrome treated with early percutaneous coronary intervention: Insights from the BASE ACS randomized controlled trial  Wail Nammas, Adam de Belder, Matti Niemelä, Jussi Sia, Hannu Romppanen, Mika Laine, Pasi P. Karjalainen  European Journal of Internal Medicine  Volume 37, Pages 43-48 (January 2017) DOI: 10.1016/j.ejim.2016.07.027 Copyright © 2016 European Federation of Internal Medicine Terms and Conditions

Fig. 1 Kaplan–Meier estimates of the primary endpoint (a composite of cardiac death, non-fatal myocardial infarction, or ischemia-driven target lesion revascularization) in the two subgroups at long-term follow-up. MACE indicates major adverse cardiac events. European Journal of Internal Medicine 2017 37, 43-48DOI: (10.1016/j.ejim.2016.07.027) Copyright © 2016 European Federation of Internal Medicine Terms and Conditions

Fig. 2 Stent-based analyses of the 2 subgroups at long-term follow-up. BAS indicates bioactive stents; EES, everolimus-eluting stents; MACE, major adverse cardiac events; MI, myocardial infarction; ST, stent thrombosis; TLR, target lesion revascularization. European Journal of Internal Medicine 2017 37, 43-48DOI: (10.1016/j.ejim.2016.07.027) Copyright © 2016 European Federation of Internal Medicine Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.